Aclidinium bromide

Aclidinium bromide
Clinical data
Trade names	Bretaris Genuair, Eklira Genuair, Tudorza Pressair
License data	US FDA: Aclidinium;
Routes of; administration	Inhalational
ATC code	R03BB05 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name [(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide;
CAS Number	320345-99-1 ;
PubChem CID	11519741;
ChemSpider	9694529 ;
UNII	UQW7UF9N91;
KEGG	D08837 ;
ChEBI	CHEBI:65344 ;
ChEMBL	ChEMBL551466 ;
CompTox Dashboard (EPA)	DTXSID30185854 ;
ECHA InfoCard	100.260.213
Chemical and physical data
Formula	C26H30BrNO4S2
Molar mass	564.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Br-].O=C(O[C@@H]3C2CC[N+](CCCOc1ccccc1)(CC2)C3)C(O)(c4sccc4)c5sccc5;
	InChI InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1 ; Key:XLAKJQPTOJHYDR-QTQXQZBYSA-M ;
	(what is this?) (verify)

Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist approved in the US on July 24, 2012^[1] as a maintenance treatment for chronic obstructive pulmonary disease (COPD).^[2]

Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD.^[3] However, it does not appear to affect the risk of death or the frequency steroids are needed.^[3] It is unclear if it differs from the similar medication tiotropium or another commonly used medication class of LAMAs.^[3]

Aclidinium is delivered via a multidose dry powder inhaler, the Genuair inhaler.

Brand names

It is marketed under the brand name Tudorza Pressair in the US, Eklira Genuair in the UK, and Tudorza Genuair in Canada; licensed to Menarini under the brand name Bretaris Genuair for majority of EU member states^[4]

References

^ "Forest Laboratories and Almirall Announce FDA Approval of Tudorza™ Pressair™ for the Long-Term Maintenance Treatment of COPD" (Press release). Forest Laboratories. Retrieved 2012-07-24.
^ Gavaldà A, Miralpeix M, Ramos I; et al. (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ ^a ^b ^c Ni, H; Soe, Z; Moe, S (Sep 19, 2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease". The Cochrane database of systematic reviews. 9: CD010509. doi:10.1002/14651858.CD010509.pub2. PMID 25234126.
^ "Almirall and Menarini sign a licence agreement and commercial alliance for Aclidinium in the majority of European member states and a number of non-EU countries" (Press release). Menarini. Retrieved 2012-03-26.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] "Forest Laboratories and Almirall Announce FDA Approval of Tudorza™ Pressair™ for the Long-Term Maintenance Treatment of COPD" (Press release). Forest Laboratories. Retrieved 2012-07-24.

[Gavalda2009-2] Gavaldà A, Miralpeix M, Ramos I; et al. (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Cochrane2014-3] Ni, H; Soe, Z; Moe, S (Sep 19, 2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease". The Cochrane database of systematic reviews. 9: CD010509. doi:10.1002/14651858.CD010509.pub2. PMID 25234126.

[4] "Almirall and Menarini sign a licence agreement and commercial alliance for Aclidinium in the majority of European member states and a number of non-EU countries" (Press release). Menarini. Retrieved 2012-03-26.

[1]

[2]

[3]

[4]